Award
National Cancer Institute 5R42CA257797-03
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
Recipient
SARYA, LLC
Award Amount
$974,650.00
Ceiling
$974,650.00
Awarded
August 20, 2024
Identifier
5R42CA257797-03
Award to Sarya LLC for developing a novel PET imaging agent to improve diagnosis and treatment of multiple myeloma, addressing limitations of current imaging methods.
Description
Sarya LLC aims to develop and commercialize a new PET imaging agent, 64Cu-LLP2A, for diagnosing, staging, and treating multiple myeloma (MM). MM is a common blood cancer with significant mortality. Current imaging methods like FDG-PET have limitations due to low uptake in MM cells and inflammatory interference. The new agent seeks to provide a more sensitive and specific diagnostic tool. Research goals include dose escalation and toxicity testing in mice, submission of amended eIND to FDA, and a clinical trial to evaluate efficacy in humans.